Overview

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

Status:
COMPLETED

Trial end date:
2024-10-31

Target enrollment:

Participant gender:

Summary

To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.

Phase:

PHASE2

Details

Lead Sponsor:

Bateman Horne Center

Treatments:

DMAC2L protein, human